News | November 10, 2024
Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
Q2 FY25 Total Income was at Rs. 85.4 crore
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Subscribe To Our Newsletter & Stay Updated
